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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYCRISPR/Cas9 protein fused to transactivation domains can be used to control gene expression in human cells. In this study, we demon-
strate that a dCas9 fusion with repeats of VP16 activator domains can efficiently activate human genes involved in pluripotency in
various cell types. This activator in combinationwith guide RNAs targeted to theOCT4 promoter can be used to completely replace trans-
genic OCT4 in human cell reprogramming. Furthermore, we generated a chemically controllable dCas9 activator version by fusion with
the dihydrofolate reductase (DHFR) destabilization domain. Finally, we show that the destabilized dCas9 activator can be used to control
human pluripotent stem cell differentiation into endodermal lineages.INTRODUCTION
Clustered regularly interspaced short palindromic repeats
(CRISPR)-based systems have recently attracted a lot of
attention due to their potential in biotechnological appli-
cations. CRISPRs originate from prokaryotic immune
response systems and have been engineered to suit genome
editing and transcriptional control purposes (Mali et al.,
2013a). The most commonly utilized CRISPR system is
derived from Streptococcus pyogenes and consists of a single
CRISPR-associated (Cas) protein, Cas9, and small guide
RNAs (gRNAs), either as two separate RNAs or fused into a
single chimeric guide RNA. The complex formed by Cas9
and gRNA binds to DNA sequences complementary to
the gRNA, upon which the Cas9 protein generates a
double-strand break in the DNA. Modified versions of the
Cas9 protein have been engineered bymutating important
catalytical residues, generating Cas9 proteins that cut only
one DNA strand (nickase Cas9) or that are completely inac-
tive (Jinek et al., 2012). Catalytically inactivated Cas9 pro-
teins (dead Cas9, dCas9) can be used to control gene
expression, either by physically interfering with the
transcription process (Gilbert et al., 2013; Qi et al., 2013)
or as fusion proteins with factors that mediate transcrip-
tional repression or activation (Bikard et al., 2013; Cheng
et al., 2013; Gilbert et al., 2013; Hu et al., 2014; Maeder
et al., 2013a; Mali et al., 2013b; Perez-Pinera et al.,
2013). These systems have recently been utilized to
mediate target gene activation and repression in mouse
and human cells to promote differentiation of human cells
(Chavez et al., 2015; Kearns et al., 2014) and transdifferen-
tiation and reprogramming of mouse cells (Chakraborty
et al., 2014; Gao et al., 2014). Moreover, various externally448 Stem Cell Reports j Vol. 5 j 448–459 j September 8, 2015 j ª2015 The Acontrollable Cas9 proteins have recently been described for
gene editing using split Cas9 architecture with either rapa-
mycin-inducible dimerization domains (Zetsche et al.,
2015) or tamoxifen-dependent intein splicing (Davis
et al., 2015).
In this study, we describe an efficient dCas9 activator
with multimeric VP16 activation domain and a simplified
method for guide RNA assembly and cloning. We demon-
strate that the dCas9 activator can be fused to a dihydrofo-
late reductase (DHFR)-derived destabilization domain (DD)
(Iwamoto et al., 2010) and used to control gene expression
with addition of Trimethoprim (TMP) in multiple human
cell types. Furthermore, we demonstrate that the dCas9
activator can be used to replace transgenic OCT4 in human
cell reprogramming and that human pluripotent cell differ-
entiation can be induced by the activator in a TMP-depen-
dent manner.RESULTS
dCas9-Transactivator Optimization for Induction of
OCT4 Expression
We introduced a second mutation to the previously pub-
lished nicking version of humanized Streptococcus pyogenes
Cas9 (Cong et al., 2013) to incorporate both D10A and
H840A mutations that render it catalytically inactive
(dCas9). This protein was then C-terminally fused with
three repeats of the PADALDDFDLDML sequence of the
Herpes simplex virus protein 16 (VP16) transactivation
domain (Baron et al., 1997), generating the dCas9VP48
activator version. The function of the construct was vali-
dated in reporter HEK293 cells, where GFP expression isuthors
under the control of TetON promoter. After targeting
dCas9VP48 to the TetON promoter with different gRNAs,
we observed increased number of GFP-positive cells in
the condition with TetOp2 gRNA, which binds four times
to the TetON promoter sequence (Figure S1). Thus,
dCas9VP48 showed transcriptional activation activity
when targeted multiple times to a promoter sequence.
Most studies so far have used dCas9 activators with VP16
transactivation sequences repeated between three and ten
times (Cheng et al., 2013; Maeder et al., 2013a; Mali
et al., 2013b; Perez-Pinera et al., 2013). To test the effect
of increasing the number of VP16 repeat domains, we
cloned additional constructs with 6 and 12 repeats of the
VP16 sequence (hereafter referred to as dCas9VP96 and
dCas9VP192 accordingly) (Figure 1A) and targeted the
endogenous OCT4 (POU5F1) promoter proximal area in
HEK293 cells using five gRNAs. Efficient OCT4 upregula-
tion was detected both at mRNA and protein level (Figures
1B and 1C). As dCas9VP192 caused the highest increase in
OCT4 expression levels, up to 70-fold, it was used for
further experiments.
dCas9VP192-Assisted Transcriptional Activation of
Pluripotency Genes
We next tested the upregulation of additional endoge-
nous pluripotency genes SOX2, NANOG, LIN28, KLF4,
and CDH1 (E-Cadherin) in HEK293 cells by targeting
dCas9VP192 to their promoters with five different gRNAs.
Single gRNA transcriptional units were assembled by PCR
and pooled and transfected together with dCas9VP192 en-
coding plasmid (Figure 1D). Expression of targeted endog-
enous factors could be detected by immunocytochemistry
72 hr after transfection (Figure 1E). PCR-gRNA fragments
were then concatenated and cloned into plasmids using
Golden Gate assembly (Figure 1D) and tested by
transfection into HEK293 cells. Immunocytochemistry
and qRT-PCR analysis showed activation of the endoge-
nous-targeted genes (Figures 1F and 1G). OCT4, SOX2,
NANOG, and CDH1 transcription was upregulated more
than 20-fold over basal levels. LIN28 and KLF4 activation
was more modest, possibly indicating either a less permis-
sive chromatin state in the promoter of these genes or a
high basal expression in HEK293 cells. These results
showed that our method enables rapid testing of many
gRNA candidates, which are easily generated with a single
PCR. The subsequent concatenation of the successful
ones in a single-step reaction allows for easy cloning of
the guides into varying vectors.
To study the ability of the gRNA-encoding plasmids and
the dCas9VP192 to activate gene expression in human skin
fibroblasts, we cloned the dCas9VP192 activator and the
concatenated guides into transiently replicating OriP-
EBNA1-containing plasmids (Okita et al., 2011). HumanStem Cellskin fibroblasts were electroporated with dCas9VP192-
EBNA and gRNA-encoding-EBNA plasmids. Activation of
endogenous OCT4, SOX2, and LIN28A but not NANOG
could be detected in cells 6 days after electroporation by
immunocytochemistry and OCT4 and SOX2 activation
by qRT-PCR (Figures 2A–2C).
Reprogramming Factor OCT4 Replaced by
dCas9VP192-Mediated Gene Activation
It has been previously demonstrated that dCas9 activators
containing between four and ten VP16 repeats can be used
to replace transgenic Oct4 in mouse fibroblast reprogram-
ming by targeting the Oct4 distal enhancer (Gao et al.,
2014). To determine whether dCas9VP192-mediated
OCT4 activationwouldwork inhumancell reprogramming,
we substituted the transgenicOCT4plasmid in theepisomal
reprogramming protocol by dCas9VP192 and OCT4 pro-
moter targeting guides (Okita et al., 2011; Yu et al., 2009)
(Figure 2D). Activation of endogenous OCT4 could be de-
tected in electroporated human skin fibroblasts expressing
the dominant-negative form of p53 by day 6 of reprogram-
ming (Figure 2E). Early colonies formed by day 9 of reprog-
ramming and classical alkaline phosphatase positive (AP+)
iPSC colonies were detected by day 18 (Figure 2F). Control
conditions, where OCT4 guide plasmid had been replaced
with GFP encoding plasmid, did not result in AP+ colony
formation or endogenous OCT4 activation (Figure 2E).
We cloned short hairpin RNA for p53 into the
dCas9VP192 plasmid to enable transient p53 inhibition
in healthy fibroblasts during reprogramming. To compare
the reprogramming efficiency of dCas9VP192-mediated
endogenous OCT4 activation to transgenic OCT4 expres-
sion, we electroporated adult human skin fibroblasts with
the reprogramming constructs and assessed the reprogram-
ming efficiency by colony morphology and AP positivity.
The colony formation efficiency was not found to differ
significantly between themethods (0.0054% of plated cells
for OCT4 activation versus 0.0021% for transgenic OCT4)
(Figure 2G). Using sh-p53-dCas9VP192 construct and
OCT4 targeting guides instead of exogenous OCT4
plasmid, we successfully derived iPSC from skin fibroblasts
obtained from a 14-year-old donor with permanent
neonatal diabetes mellitus (PNDM) and from a healthy
72-year-old donor (F72) (Figures S2A and S2B). The derived
iPSC colonies were propagated for at least ten passages. All
iPSC colonies expressed OCT4, NANOG, TRA-1-60, and
TRA-1-81 (Figure 2H), and qRT-PCR analysis verified the
expression of additional pluripotencymarkers (Figure S2A).
iPSC lines were able to differentiate into the three germline
derivatives positive for FOXA2 (endoderm), VIMENTIN
(mesoderm), and bIII-TUBULIN (ectoderm) in embryoid
bodies (Figure 2I). Clearance of the episomal reprogram-
ming plasmids was confirmed in 12 of 17 iPSC clones inReports j Vol. 5 j 448–459 j September 8, 2015 j ª2015 The Authors 449
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Figure 1. Strategy for dCas9-Mediated Activation of Pluripotency Genes
(A) Schematic representation of dCas9 activator versions tested.
(B) Upregulation of OCT4 in HEK293 cells by different dCas9 activator versions. Relative mRNA expression levels were measured by qRT-PCR
72 hr after transfection. VP96-only transfection was used as control. Data represent mean ± SEM, n = 5 independent transfections.
(C) Immunocytochemical analysis of OCT4 in HEK293 cells 72 hr after transfection with dCas9 activator versions and OCT4 targeting gRNAs.
Scale bars represent 400 mm.
(D) Schematic representation of the gRNA cloning and testing strategy. gRNAs were first validated with PCR-amplified fragments before
concatenating them into plasmids by Golden Gate assembly.
(legend continued on next page)
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passage 2 (Figure S2B). Thus, human skin fibroblasts can be
reprogrammed into iPSC by replacing OCT4 overexpres-
sion with dCas9 activator-mediated activation of endoge-
nous OCT4.
Conditionally Stabilized dCas9 Activator
In order to control temporally the activity of the dCas9 acti-
vator, we fused the protein N-terminally to the E. coli-
derived DHFR DD. This allowed us to control the stability
of the activator in a TMP-dependent manner (Figure 3A).
To test the construct in gene activation, we initially
created a destabilized version of the dCas9VP48 activator
(DDdCas9VP48) and generated HEK293 cells constitu-
tively expressing DDdCas9VP48 with and without OCT4
targeting guides. In the absence of guides, OCT4 expression
was not detected in the cells (Figure S3A). In the presence of
guides, only some leakyOCT4 expression could be detected
in a minor population of cells, which was drastically
increased upon addition of TMP (Figure S3A).
To compare the TMP-inducible dCas9 system with the
more commonly used doxycycline inducible TetON sys-
tem, we generated stable HEK293 cell lines with TetON-
dCas9VP192, constitutive DDdCas9VP192, or TetON-
DDdCas9VP192 and guides targeting the OCT4 promoter.
Both TetON-dCas9VP192 and DDdCas9VP192 performed
comparably (Figures 3B and 3C), presenting leaky expres-
sion at non-induced d0 samples, and upregulation of
OCT4 after addition of doxycycline or TMP, to up to 5.2
and 6.6 times the expression levels of human embryonic
stem cells (hESCs) accordingly. The combination of both
TetONpromoter andDHFRDDwith the dCas9VP192 elim-
inated the nonspecific activation ofOCT4 in the absence of
doxycycline or TMP (Figures 3B and 3C).
We then generated HEK293 cells constitutively express-
ing the DDdCas9VP192 activator and guides targeting
OCT4, SOX2, NANOG, and LIN28A promoters simulta-
neously. Some leaky activation of OCT4 and SOX2 but
not NANOG or LIN28A could be detected in cells not
treated with TMP (Figure 3D). After addition of TMP, the
expression of OCT4, SOX2, and NANOG increased already
by day 1, reaching 24%, 187%, and 41% of the expression
levels measured in hESC (H9), respectively (Figure 3D). In
contrast to the other factors, LIN28A upregulation was
not detected by qRT-PCR (Figure 3D). Unlike the strongly
activated OCT4, LIN28A expression could be detected in
only a few cells by immunocytochemistry (Figure 3E).(E) Immunocytochemical detection of the products of the targeted gen
and dCas9VP192 plasmid. Non-treated (NT) HEK293 cells were used a
(F) Activation of targeted genes in HEK293 cells transfected with g
represent 200 mm.
(G) Upregulation of mRNA levels of targeted genes measured by qRT-P
plasmids and dCas9VP192 plasmid. Data represent mean ± SEM, n = 2
Stem CellTo test the activator in primary human cells, we gener-
ated F72 human skin fibroblasts constitutively expressing
the DDdCas9VP192 and OCT4, SOX2, NANOG, and
LIN28A promoter targeting guides. Leaky activation was
not detected in the fibroblasts in the absence of TMP (d0,
Figures 3F and 3G). In the presence of TMP, OCT4, SOX2,
and NANOG expression rose gradually reaching highest
expression of 46%, 63%, and 7% of hESC levels, respec-
tively, by the end of the 9-day period (Figure 3F). LIN28A
upregulation was not robustly detected by qRT-PCR in fi-
broblasts (Figure 3F), but rare positive cells could be de-
tected by immunocytochemistry (Figure 3G).
In an attempt to improve the activation efficiency of the
target genes in the fibroblasts, we tested a set of inhibitors
commonly used for iPSC induction to explore whether
chemical compounds could improve dCas9VP192-medi-
ated gene activation. However, treatment with these inhib-
itors did not significantly increase target gene activation ef-
ficiency (Figures S3B–S3D).
Activation of Endodermal and Pancreatic
Transcription Factors by dCas9VP192
In order to examine the versatility of our method in
activating different genes, we targeted a set of endo-
dermal and pancreatic master transcription factors with
dCas9VP192. We designed gRNAs targeting the proximal
promoters of FOXA2, SOX17, GATA4, PDX1, and NKX6.1,
PCR-amplified and tested them as described above. After
preliminary confirmation of gene activation by immuno-
cytochemistry, gRNAs were concatenated and validated
inHEK293 cells. Analysis at 72 hr after transfection showed
clear activation of the tested genes at the protein and
mRNA level (Figure S4A).
Activation of endodermal transcription factor SOX17
using a dCas9 activator has been reported to work effi-
ciently in hESCs (Kearns et al., 2014). To address whether
our set of genes could be upregulated by dCas9VP192 in
pluripotent stem cells, we transfected dCas9VP192 plus
gRNA-encoding plasmids to human iPSCs. After 72 hr, acti-
vation of all the five tested genes was detected by immuno-
cytochemistry and confirmed by qRT-PCR (Figures 4A, 4B,
and S4C), demonstrating that dCas9VP192 can drive the
expression of differentiation-relevant transcription factors
also in pluripotent cells.
Next we generated a hESC line (H9) constitutively ex-
pressing DDdCas9VP192 activator and gRNAs targetinges in HEK293 cells 72 hr after transfection with PCR gRNA fragments
s staining control. Scale bars represent 200 mm.
RNA-concatenated plasmids and dCas9VP192 plasmid. Scale bars
CR in HEK293 cells 72 hr after transfection with gRNA-concatenated
–4 independent transfections.
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Figure 2. Functional Validation of dCas9 Activator in Reprogramming to Pluripotency
(A) Schematic representation of factors targeted in human skin fibroblasts with the dCasVP192 in transient electroporation.
(B and C) qRT-PCR and immunocytochemical detection of the targeted pluripotency factors 6 days after electroporation of human skin
fibroblasts with dCas9VP192-EBNA and gRNA-encoding-EBNA. Scale bars represent 400 mm.
(D) Schematic representation of factors used in OCT4 replacement reprogramming protocol.
(legend continued on next page)
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the endodermal transcription factors FOXA2 and SOX17
and the pancreatic factors PDX1 and NKX6.1 to test the
applicability of this system in directed differentiation.
The H9-DDdCas9VP192 cells were treated for 3 days
following an endodermal differentiation protocol (Rezania
et al., 2014) (Supplemental Experimental Procedures)
either in the complete medium including Activin A (AA)
(TMP +AA condition), without Activin A as a control
(TMP AA), or with 1 mM TMP and no Activin A
(+TMP AA) (Figure 4C). As expected, the cells treated for
3 days with AA differentiated into FOXA2+/SOX17+ defini-
tive endoderm but did not express pancreatic progenitor
marker genes (Figures 4D and S4D). In contrast, the
simultaneous activation of endodermal and pancreatic
transcription factors upon the addition of TMPupregulated
pancreatic progenitor markers in the same time period.
These cells expressed FOXA2, SOX17, PDX1, and NKX6.1
directly activated by DDdCas9VP192 (Figures 4D, 4E, and
S4D). Importantly, also their downstream target transcrip-
tion factors SOX9 and NKX2.2 were induced at both the
mRNA and protein levels (Figures 4D and 4E).
To demonstrate the feasibility of using DDdCas9VP192
target gene activation in combination with other inducible
expression systems, we generated a transgenic hESC line
expressing DDdCas9VP192 activator, gRNAs targeting the
pancreatic transcription factors PDX1 and NKX6.1, and a
doxycycline-inducible overexpression cassette for mature
beta cell transcription factor MAFA (TetON-MAFA-ires-
GFP). The cells were treated with a pancreatic differentia-
tion protocol for 9 days (Rezania et al., 2014). The
experimental protocol is presented in Figure 4F. From
days 3 to 9, the cells were treated with 1 mMTMP to induce
PDX1 and NKX6.1 expression and from day 7 to 9 with
1 mg/ml doxycycline to induce MAFA (Figure 4F). At both
days 7 and 9 of differentiation, PDX1 and NKX6.1 expres-
sion levels were increased in the +TMP condition, as shown
by qRT-PCR and immunocytochemistry (Figures 4G and
4H). MAFA overexpression was robustly detected in the
doxycycline-treated conditions at day 9, together with(E) Immunocytochemical detection of activation of endogenous OCT
electroporated with pCXLE-GFP (-CTRL), episomal SOX2, KLF4, LIN28, a
OCT4 (+CTRL). Scale bars represent 400 mm.
(F) Formation of AP+ colonies with dCas9VP192 replacing transgenic
(G) Comparison of episomal reprogramming efficiencies of adult human
or transgenic OCT4 together with transgenic SOX2, KLF4, LIN28, L-MY
experiments, p = 0.177 using Student’s t test.
(H) Immunocytochemical detection of pluripotency markers TRA-1-81
human fibroblasts with transgenic OCT4 replacement by dCas9VP192
(I) Immunocytochemical detection of markers of different germ lay
fibroblasts by transgenic OCT4 replacement using dCas9VP192.FOXA2 (
Scale bars represent 200 mm for VIMENTIN.
See also Figure S2.
Stem Cellthe upregulation of MAFA downstream target glucokinase
(GCK) (Figures 4G and 4H) (Wang et al., 2007). These re-
sults demonstrate that the two inducible systems can be
combined to control the expression of specific genes at
distinct time points of the differentiation process.
Finally, we also tested these constructs in primary human
foreskin fibroblasts. Endogenous gene activation was de-
tected at protein and mRNA level (Figure S4B), albeit at
low efficiency, indicating that dCas9VP192 can activate
endodermal gene transcription even in somatic cells with
a more restrictive epigenetic landscape.DISCUSSION
We report on the ability of dCas9 activators to upregulate
the expression of endogenous human genes associated
with reprogramming and maintenance of pluripotency as
well as differentiation. We optimized the dCas9 activator
efficiency and described a simplified workflow for testing
and cloning the guide RNAs. The potent functional effect
of the dCas9VP192 was demonstrated by replacing trans-
genic OCT4 with the activator in the reprogramming of
primary human fibroblasts into iPSCs. Furthermore, we
converted the activator into a conditionally stabilized
version, which can be controlled by a smallmolecular com-
pound, and demonstrated its function in controlling cell
differentiation.
Our results show that increasing the number of VP16
transactivator repeats fused to dCas9 leads to improved
activation of the endogenous OCT4. Using dCas9VP192
and five gRNAs, we obtained up to 70-fold OCT4 upregula-
tion inHEK293 cells, in similar range of efficiencywith pre-
vious studies (Cheng et al., 2013; Hu et al., 2014;Mali et al.,
2013b). The fact that dCas9 activators can replace trans-
genic OCT4 as a reprogramming factor in human iPSC
derivation speaks for the functional relevance of the gene
activation and the potential for utilizing this approach
for human cell type conversions. A similar approach has4 in human skin fibroblasts on day 6 of reprogramming. Cells were
nd L-MYC plus dCas9VP192 and either OCT4 gRNAs plasmid or pCXLE-
OCT4. Scale bars represent 200 mm.
skin fibroblasts using either dCas9VP192 and OCT4 targeting guides
C, and p53 shRNA. Data represent mean ± SEM, n = 4 independent
, NANOG, OCT4, and TRA-1-60 in passage 2 iPSCs derived from normal
and SKLM transgenes. Scale bars represent 400 mm.
ers in plated embryoid bodies of iPSCs derived from PNDM human
endoderm), VIMENTIN (mesoderm), and bIII-TUBULIN (ectoderm).
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been previously demonstrated to work for mouse cell re-
programming (Chakraborty et al., 2014; Gao et al., 2014).
The potency of dCas9 activators varies between genes.
We were not able to efficiently replace additional reprog-
ramming factors, although their activation could be de-
tected in fibroblasts. As NANOG and LIN28A activation
was detected only in a minor population of cells, it is likely
that the activation of these genes is stochastic by nature
and limited by epigenetic barriers. Therefore, alternative
approaches, for example, improved transactivation do-
mains or catalytically active domains affecting the epige-
netic state of the gene regions may be needed (Chavez
et al., 2015; Hilton et al., 2015; Konermann et al., 2015;
Maeder et al., 2013b). Additionally, the size of the construct
could be reduced by incorporating multimerization sites
for the activator domains, such as the recently reported
SunTag peptide tail, which would implement an amplifica-
tion step in the recruitment of transactivators to the
proximal promoter that results in greatly enhanced gene
activation (Tanenbaum et al., 2014). Targeting noncoding
RNAs as well as genomic enhancer elements in addition
to promoter proximal areas might also help in replacing
transgenic factors with only dCas9 activators and gRNAs
(Gao et al., 2014; Hilton et al., 2015).
The power of the dCas9 system for affecting gene expres-
sion lies in the multiplexing potential of the short gRNA
sequences. Concatenation of gRNA expression cassettes
using Golden Gate cloning has recently been described
for multiplex genome editing (Sakuma et al., 2014) and
gene activation (Kabadi et al., 2014). In contrast, our
method avoids time-consuming traditional cloning for
the initial gRNA-assembly step, being substituted by a
simple PCR reaction. After gRNA efficiency validation,
the gRNA-PCR fragments are concatenated with a single
Golden Gate reaction, streamlining the generation of
gRNA-encoding plasmids for different target genes. The
small size of the gRNA construct compared with transgenic
expression methods allows for efficient simultaneous tar-
geting of multiple genomic loci and potentially full gene
regulatory networks (GRNs). As dCas9 activators are target-
ing the endogenous genes for activation, activation of the
proximal regulatory regions might benefit the establish-(C) Comparison of inducible DDdCas9, TetON-dCas9, and TetON-DDdCas
were treated for up to 5 days with 1 mM TMP (for DDdCas9), 1 mg/m
Expression levels relative to H9 hESC are represented as mean ± SEM,
(D and E) Temporal activation of OCT4, SOX2 NANOG, and LIN28A ind
immunocytochemistry in HEK293 cells expressing DDdCas9VP192 and
are represented as mean ± SEM, n = 4 independently treated samples
(F and G) Temporal activation of OCT4, SOX2 NANOG, and LIN28A induc
primary human skin fibroblasts (F72) expressing DDdCas9VP192 and
represented as mean ± SEM, n = 4 independently treated samples. Sc
See also Figure S3.
Stem Cellment of proper transcriptional programs by affecting epige-
netic barriers to the reprogramming process.
N-terminal fusion of the dCas9 activator with the DHFR
DD leads to a functional TMP-dependent dCas9 activation.
In terms of inducible gene transcription, DDdCas9 acti-
vator performs as efficiently as the TetON dCas9, with the
advantage of not requiring an additional rtTA transactiva-
tor element. The DDdCas9 activator did, however, show a
certain level of leakiness possibly due to incomplete
protein degradation. This nonspecific activation can be
controlled by combining the DDdCas9 activator with addi-
tional inducible systems like TetON, as shown in Figure 3B,
or by controlling the expression level of the activator.
Moreover, combining the S. pyogenes DDdCas9 activator
with other orthogonal Cas9-derived conditional transcrip-
tional modulators should allow for simultaneous temporal
control over multiple gene expression programs (Davis
et al., 2015; Esvelt et al., 2013; Ran et al., 2015; Zetsche
et al., 2015).
Kearns et al. (2014) demonstrated that dCas9 transcrip-
tional activators and repressors can be used to control hu-
man pluripotent stem cell differentiation by targeting
endogenous SOX17 and OCT4. We have expanded the
target gene list to additional key factors in the endodermal
and pancreatic differentiation pathways. The induction of
these genes may accelerate the differentiation of pluripo-
tent stem cells to pancreatic progenitor-like cells to only
3 days, as compared with 10 or more days needed with cur-
rent differentiation protocols (Rezania et al., 2014). The
expression in these cells of genes downstream of FOXA2,
SOX17, PDX1, and NKX6.1 indicates that simultaneous
activation of a key gene set by DDdCas9 activator could
help in establishing cell-type-specific GRNs (Arda et al.,
2013). This constitutes a method to study and improve
the differentiation of pluripotent stem cells to a particular
lineage, for example, by activation of key regulators of line-
age bifurcations or terminal differentiation. Moreover,
DDdCas9-mediated transcriptional activation of genes
can be utilized in combination with well-established over-
expression methods, as we show here for doxycycline-
inducible systems, adding an extra layer of tunable and
temporally controlled gene expression.9 activators in the upregulation of OCT4 levels in HEK293 cells. Cells
l of doxycycline (for TetON-dCas9), or both (for TetON-DDdCas9).
n = 3 independently treated samples.
uced with 1 mM TMP analyzed by qRT-PCR and OCT4 and LIN28A by
gRNAs targeting these genes. Expression levels relative to H9 hESC
. Scale bars represent 400 mm.
ed with 1 mM TMP analyzed by qRT-PCR and immunocytochemistry in
gRNAs targeting these genes. Expression levels relative to H9 hESC
ale bars represent 400 mm.
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Figure 4. Activation of Lineage-Specific Transcription Factors by dCas9VP192
(A) Immunocytochemical detection of dCas9VP192 targeted endodermal and pancreatic genes in hiPSC line HEL72.1. Scale bars represent
200 mm.
(B) qRT-PCR analysis of indicated targeted genes in hiPSC. Data represent mean ± SEM relative to non-transfected cells, n = 2 independent
transfections. Analyses in (A) and (B) were performed 72 hr after delivery of gRNA-concatenated plasmids and dCas9VP192.
(legend continued on next page)
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In the future, combining the dCas9 activators with large-
scale nucleic acid synthesis and high-throughput screening
may enable the generation of gRNA arrays to activate
simultaneously a determined set of genes (e.g., all the key
components in a GRN), providing an unprecedented level
of precision for controlling cellular reprogramming and
differentiation (Gilbert et al., 2014; Shalem et al., 2014;
Wang et al., 2014).EXPERIMENTAL PROCEDURES
Ethical Consent
The generation of the human induced pluripotent stem cell
(hiPSC) lines used in this study was approved by the Coordinating
Ethics Committee of the Helsinki and Uusimaa Hospital District
(Nro 423/13/03/00/08).
Cell Culture
HEK293 cells, skin fibroblasts derived from a 14-year-old donor
with PNDM, healthy 72-year-old skin fibroblast (F72), and human
foreskin fibroblasts (HFFs, ATCC line CRL-2429) were cultured in
fibroblast medium (DMEM; Life Technologies) containing 10%
fetal bovine serum (FBS; Life Technologies), 2 mM GlutaMAX
(Life Technologies), and 100 g/ml penicillin-streptomycin (Sigma).
hESC and hiPSCs were cultured on Matrigel-coated dishes in E8
medium (Life Technologies, A1517001) in an incubator at 37C
and 5% CO2. The HEL72.1 hiPSC cell line was retrovirally derived
from PNDM-patient fibroblasts, and in vitro differentiation
through embryoid bodies was performed as described elsewhere
(Vuoristo et al., 2013).
Guide RNA Design and Production
Guide RNA sequences were designed using the http://crispr.mit.
edu web-based tool, targeting them to the proximal promoters
(400 to 50 base pairs from transcription start site) of the gene
of interest. Possible guides were selected according to their off-
target score and position. Guide RNA transcriptional units
(gRNA-PCR) were prepared by PCR amplification and further
concatenated using Golden Gate assembly. See Supplemental
Experimental Procedures for further details.(C) Schematic representation of DDdCas9VP192-mediated activation
(D) Immunocytochemistry of hESC H9 expressing DDdCas9VP192 a
definitive endoderm at day 3. hESC treated with 100 ng/ml Activin A (
with 1 mM TMP (+TMP AA) stained for pancreatic progenitor ma
downstream targets NKX2.2 and SOX9. Scale bars represent 200 mm.
(E) qRT-PCR analysis of cells treated as in (D) at day 3 of different
samples.
(F) Schematic representation of hPSC differentiation toward pancreat
TMP-inducible DDdCas9VP192 activating PDX1 and NKX6.1 endogenou
overexpression system (days 7 to 9).
(G) qRT-PCR analysis of experiment depicted in (F). PDX1 and NKX6.
samples. MAFA and its downstream target GCK expression levels are s
mean ± SEM, n = 3 independently treated samples.
(H) Immunocytochemistry for NKX6.1 and MAFA of hESC treated as d
Stem CellPluripotent Reprogramming
For human skin fibroblast reprogramming, 1 million cells were
electroporated with Neon electroporator (Life Technologies), as
described in Supplemental Experimental Procedures. A total of
6 mg of DNA was used per electroporation, containing 2 mg of
pCXLE-dCas9VP192-GFP-shp53 and 1 mg of each other plasmids
(guide encoding EBNA plasmids and reprogramming plasmids
pCXLE-OCT4, pCXLE-hSK, and pCXLE-hUL). Afterward, electro-
porated cells were plated on gelatin-coated tissue culture dishes
in fibroblast medium. On day 6, electroporated cells were split
onto Matrigel-coated plates and cell culture medium was changed
to a 3:1 mixture of hES and fibroblast-medium. After initial colony
formation, the medium was changed to hES-medium (KnockOut
DMEM; Life Technologies) supplemented with 20% knockout
(KO) serum replacement (Life Technologies), 1% GlutaMAX,
0.1 mM beta-mercaptoethanol, 1% nonessential amino acids
(Life Technologies), and 6 ng/ml basic fibroblast growth factor
(bFGF, Life Technologies) supplemented with 0.25 mM sodium
butyrate (NaB; Sigma). Medium was changed every other day.
Emerging iPSC colonies were picked on Matrigel-coated dishes in
E8medium. P53 defective HFFs used in guide testing were infected
with dominant-negative p53DD-encoding retrovirus (Addgene
plasmid: 22729) and passaged twice before reprogramming. Clear-
ance of episomal plasmids was demonstrated by PCR (Okita et al.,
2011).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and four figures and can be found with this article
online at http://dx.doi.org/10.1016/j.stemcr.2015.08.001.
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